Patents by Inventor Steinar Hagen

Steinar Hagen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9428540
    Abstract: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: August 30, 2016
    Assignee: CLAVIS PHARMA ASA
    Inventors: Finn Myhren, Marit Liland Sandvold, Ole Henrik Eriksen, Steinar Hagen
  • Patent number: 8349834
    Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives fall within formula (I). Compounds of formula (I) can be used in the treatment of a cancerous disease, including solid tumors and haematological cancers such as leukaemias, lymphomas and multiple myelomas.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: January 8, 2013
    Assignee: Clavis Pharma AS
    Inventors: Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
  • Publication number: 20100099654
    Abstract: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.
    Type: Application
    Filed: March 13, 2008
    Publication date: April 22, 2010
    Applicant: CLAVIS PHARMA ASA
    Inventors: Myhren Finn, Marit Liland Sandvold, Ole Henrik Eriksen, Steinar Hagen
  • Publication number: 20100062996
    Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.
    Type: Application
    Filed: December 7, 2006
    Publication date: March 11, 2010
    Applicant: CLAVIS PHARMA AS
    Inventors: Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
  • Publication number: 20070135436
    Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula I” herein. Compounds of formula I can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.
    Type: Application
    Filed: December 19, 2005
    Publication date: June 14, 2007
    Applicant: Clavis Pharma AS
    Inventors: Finn Myhren, Marit Sandvold, Steinar Hagen, Ole Eriksen
  • Patent number: 6569911
    Abstract: A method of manufacturing a support media from a cross-linked polymerisate based on vinyl compounds, and exhibiting residual vinyl groups. The characteristic feature of the method is that the polymerisate is subjected to a heating step that preferably is carried out under reduced access of oxygen. The use of the support media is also described.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: May 27, 2003
    Assignee: Amersham Biosciences AB
    Inventors: Torunn Arntsen, Jan Roger Karlson, Geir Fonnum, Steinar Hagen
  • Patent number: 6420028
    Abstract: A polymer article having structure (I), where P comprises the basic polymer and groups —L—CH(—X(R1)p)—CH2(—Y(R2)p); L is a part of a pending group utilized for introducing —X(R1)p and —Y(R2)p; X and Y are halogen, N, S and O; R1 is hydrogen, alkyl, acyl or R2 when X is N, O or S; R2 is hydrogen, alkyl, alkylaryl or arylalkyl in which the alkyl part may contain 1-18 carbons, or —R3(—NH—CR4═O)q or —R3(—NH2)q, —CR4═O or poly alkyloxy that may have been terminally acylated or alkylated; p is an integer 0-3, with the provisos a) p depends on X being halogen, O, S or N, and b) that if several groups R2 are present they may be identical or different; R3 is alkyl, —O-alkyl, hydroxyalkyl, phenylalkyl, with up to 18 carbon atoms in the alkyl part, and R4 is C1-18 alkyl. q is an integer>O representing that one or more hydrogens in R3 may have been replaced with —NH2 or —NH—CR4═O.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: July 16, 2002
    Assignee: Amersham Pharmacia Biotech AB
    Inventors: Steinar Hagen, Rune Ringberg, Geir Fonnum